Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity
- 249 Downloads
Lung cancer is the first leading cause of cancer deaths. Chemotherapy toxicity is one of factors that limited the efficacy of platinum-based chemotherapy in lung cancer patients. Transporters and DNA repair genes play critical roles in occurrence of platinum-based chemotherapy toxicity. To investigate the relationships between transporter and DNA repair gene polymorphisms and platinum-based chemotherapy toxicity in lung cancer patients, we selected 60 polymorphisms in 14 transporters and DNA repair genes. The polymorphisms were genotyped in 317 lung cancer patients by Sequenom MassARRAY. Logistic regression was performed to estimate the association of toxicity outcome with the polymorphisms by PLINK. Our results showed that polymorphisms of SLC2A1 (rs3738514, rs4658, rs841844) were significantly related to overall toxicity. XRCC5 (rs1051685, rs6941) and AQP2 (10875989, rs3759125) polymorphisms were associated with hematologic toxicity. AQP2 polymorphisms (rs461872, rs7305534) were correlated with gastrointestinal toxicity. In conclusion, genotypes of these genes may be used to predict the platinum-based chemotherapy toxicity in lung cancer patients.
KeywordsLung cancer Platinum Chemotherapy toxicity Genetic polymorphism Transporter DNA repair gene
This work was supported by the National High-tech R&D Program of China (863 Program) (2012AA02A517, 2012AA02A518), National Natural Science Foundation of China (81173129, 81202595, 81373490, 81273595), and the Fundamental Research Funds for the Central Universities of Central South University (2015zzts116).
Conflicts of interest
- 1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin. 2015;65:5–29.Google Scholar